Median cost per patient for orphan drugs is 5.5 times higher, report says

28 February 2017

A report on orphan drugs has shown that the median cost per patient is 5.5 times higher for orphan drugs compared to other medicines.

The average US cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, according to the EvaluatePharma Orphan Drug 2017 Report.

It also predicts continued growth at a compound annual growth rate from 2017 to 2022 of 11.1% for orphan drugs, approximately double overall prescription market growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical